ID   TAF1_HUMAN              Reviewed;        1872 AA.
AC   P21675; A5CVC8; A5CVC9; A5CVD0; A5CVD1; B1Q2X3; Q59FZ3; Q6IUZ1; Q70Q86;
AC   Q70Q87; Q70T00; Q70T01; Q70T02; Q70T03;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 2.
DT   12-OCT-2022, entry version 233.
DE   RecName: Full=Transcription initiation factor TFIID subunit 1;
DE            EC=2.3.1.48 {ECO:0000269|PubMed:15870300};
DE            EC=2.7.11.1;
DE   AltName: Full=Cell cycle gene 1 protein;
DE   AltName: Full=TBP-associated factor 250 kDa;
DE            Short=p250;
DE   AltName: Full=Transcription initiation factor TFIID 250 kDa subunit;
DE            Short=TAF(II)250;
DE            Short=TAFII-250;
DE            Short=TAFII250;
GN   Name=TAF1; Synonyms=BA2R, CCG1, CCGS, TAF2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Laryngeal carcinoma;
RX   PubMed=2038334; DOI=10.1128/mcb.11.6.3317-3325.1991;
RA   Sekiguchi T., Nohiro Y., Nakamura Y., Hisamoto N., Nishimoto T.;
RT   "The human CCG1 gene, essential for progression of the G1 phase, encodes a
RT   210-kilodalton nuclear DNA-binding protein.";
RL   Mol. Cell. Biol. 11:3317-3325(1991).
RN   [2]
RP   PRELIMINARY NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3169001; DOI=10.1002/j.1460-2075.1988.tb02996.x;
RA   Sekiguchi T., Miyata T., Nishimoto T.;
RT   "Molecular cloning of the cDNA of human X chromosomal gene (CCG1) which
RT   complements the temperature-sensitive G1 mutants, tsBN462 and ts13, of the
RT   BHK cell line.";
RL   EMBO J. 7:1683-1687(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH TBP AND TAFS.
RX   PubMed=7680771; DOI=10.1038/362175a0;
RA   Ruppert S., Wang E.H., Tjian R.;
RT   "Cloning and expression of human TAFII250: a TBP-associated factor
RT   implicated in cell-cycle regulation.";
RL   Nature 362:175-179(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM N-TAF1), AND INVOLVEMENT IN DYT3.
RC   TISSUE=Brain;
RX   PubMed=17273961; DOI=10.1086/512129;
RA   Makino S., Kaji R., Ando S., Tomizawa M., Yasuno K., Goto S., Matsumoto S.,
RA   Tabuena M.D., Maranon E., Dantes M., Lee L.V., Ogasawara K., Tooyama I.,
RA   Akatsu H., Nishimura M., Tamiya G.;
RT   "Reduced neuron-specific expression of the TAF1 gene is associated with X-
RT   linked dystonia-parkinsonism.";
RL   Am. J. Hum. Genet. 80:393-406(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT VAL-269.
RG   NIEHS SNPs program;
RL   Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 837-1872 (ISOFORM 4).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1347-1801 (ISOFORMS 2A; 2C AND 2D),
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1347-1592 (ISOFORM 2E), NUCLEOTIDE SEQUENCE
RP   [MRNA] OF 1498-1801 (ISOFORM 3), AND INVOLVEMENT IN DYT3.
RC   TISSUE=Fetal brain;
RX   PubMed=12928496; DOI=10.1073/pnas.1831949100;
RA   Nolte D., Niemann S., Muller U.;
RT   "Specific sequence changes in multiple transcript system DYT3 are
RT   associated with X-linked dystonia parkinsonism.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:10347-10352(2003).
RN   [9]
RP   SEQUENCE REVISION.
RA   Nolte D.;
RL   Submitted (MAY-2007) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1347-1801 (ISOFORMS 2E; 2G; 2H AND 2I), AND
RP   ALTERNATIVE SPLICING.
RX   PubMed=17952504; DOI=10.1007/s00335-007-9063-z;
RA   Herzfeld T., Nolte D., Muller U.;
RT   "Structural and functional analysis of the human TAF1/DYT3 multiple
RT   transcript system.";
RL   Mamm. Genome 18:787-795(2007).
RN   [11]
RP   FUNCTION.
RX   PubMed=8450888; DOI=10.1038/362179a0;
RA   Hisatake K., Hasegawa S., Takada R., Nakatani Y., Horikoshi M.,
RA   Roeder R.G.;
RT   "The p250 subunit of native TATA box-binding factor TFIID is the cell-cycle
RT   regulatory protein CCG1.";
RL   Nature 362:179-181(1993).
RN   [12]
RP   FUNCTION, ACTIVITY REGULATION, PHOSPHORYLATION AT SER-137 AND SER-307, AND
RP   ATP-BINDING.
RX   PubMed=8625415; DOI=10.1016/s0092-8674(00)81055-7;
RA   Dikstein R., Ruppert S., Tjian R.;
RT   "TAFII250 is a bipartite protein kinase that phosphorylates the base
RT   transcription factor RAP74.";
RL   Cell 84:781-790(1996).
RN   [13]
RP   INTERACTION WITH SV40 LARGE T ANTIGEN (MICROBIAL INFECTION).
RX   PubMed=8647434; DOI=10.1101/gad.10.11.1369;
RA   Damania B., Alwine J.C.;
RT   "TAF-like function of SV40 large T antigen.";
RL   Genes Dev. 10:1369-1381(1996).
RN   [14]
RP   INTERACTION WITH HERPES SIMPLEX VIRUS 1 ICP4 (MICROBIAL INFECTION).
RX   PubMed=8649420; DOI=10.1128/mcb.16.6.3085;
RA   Carrozza M.J., DeLuca N.A.;
RT   "Interaction of the viral activator protein ICP4 with TFIID through
RT   TAF250.";
RL   Mol. Cell. Biol. 16:3085-3093(1996).
RN   [15]
RP   FUNCTION, AND MUTAGENESIS.
RX   PubMed=9660973; DOI=10.1016/s1097-2765(00)80089-1;
RA   O'Brien T., Tjian R.;
RT   "Functional analysis of the human TAFII250 N-terminal kinase domain.";
RL   Mol. Cell 1:905-911(1998).
RN   [16]
RP   FUNCTION, ACTIVITY REGULATION, INTERACTION WITH RB1, AND ATP-BINDING.
RX   PubMed=9858607; DOI=10.1128/mcb.19.1.846;
RA   Siegert J.L., Robbins P.D.;
RT   "Rb inhibits the intrinsic kinase activity of TATA-binding protein-
RT   associated factor TAFII250.";
RL   Mol. Cell. Biol. 19:846-854(1999).
RN   [17]
RP   INTERACTION WITH ASF1A.
RX   PubMed=10759893; DOI=10.1046/j.1365-2443.2000.00319.x;
RA   Munakata T., Adachi N., Yokoyama N., Kuzuhara T., Horikoshi M.;
RT   "A human homologue of yeast anti-silencing factor has histone chaperone
RT   activity.";
RL   Genes Cells 5:221-233(2000).
RN   [18]
RP   FUNCTION.
RX   PubMed=11278496; DOI=10.1074/jbc.m009385200;
RA   Solow S., Salunek M., Ryan R., Lieberman P.M.;
RT   "Taf(II) 250 phosphorylates human transcription factor IIA on serine
RT   residues important for TBP binding and transcription activity.";
RL   J. Biol. Chem. 276:15886-15892(2001).
RN   [19]
RP   ACTIVITY REGULATION, AND INTERACTION WITH TAF7.
RX   PubMed=11592977; DOI=10.1073/pnas.211444798;
RA   Gegonne A., Weissman J.D., Singer D.S.;
RT   "TAFII55 binding to TAFII250 inhibits its acetyltransferase activity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:12432-12437(2001).
RN   [20]
RP   INTERACTION WITH ASF1A.
RX   PubMed=12093919; DOI=10.1073/pnas.142627899;
RA   Chimura T., Kuzuhara T., Horikoshi M.;
RT   "Identification and characterization of CIA/ASF1 as an interactor of
RT   bromodomains associated with TFIID.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:9334-9339(2002).
RN   [21]
RP   INTERACTION WITH ASF1A AND ASF1B.
RX   PubMed=12842904; DOI=10.1074/jbc.m303549200;
RA   Umehara T., Horikoshi M.;
RT   "Transcription initiation factor IID-interactive histone chaperone CIA-II
RT   implicated in mammalian spermatogenesis.";
RL   J. Biol. Chem. 278:35660-35667(2003).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH TP53.
RX   PubMed=15053879; DOI=10.1016/s1097-2765(04)00123-6;
RA   Li H.-H., Li A.G., Sheppard H.M., Liu X.;
RT   "Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for
RT   TAF1 in cell G1 progression.";
RL   Mol. Cell 13:867-878(2004).
RN   [23]
RP   IDENTIFICATION IN THE MLL1/MLL COMPLEX.
RX   PubMed=15960975; DOI=10.1016/j.cell.2005.04.031;
RA   Dou Y., Milne T.A., Tackett A.J., Smith E.R., Fukuda A., Wysocka J.,
RA   Allis C.D., Chait B.T., Hess J.L., Roeder R.G.;
RT   "Physical association and coordinate function of the H3 K4
RT   methyltransferase MLL1 and the H4 K16 acetyltransferase MOF.";
RL   Cell 121:873-885(2005).
RN   [24]
RP   HISTONE ACETYLTRANSFERASE ACTIVITY, AND MUTAGENESIS OF GLU-721 AND
RP   827-MET--ASP-829.
RX   PubMed=15870300; DOI=10.1128/mcb.25.10.4321-4332.2005;
RA   Hilton T.L., Li Y., Dunphy E.L., Wang E.H.;
RT   "TAF1 histone acetyltransferase activity in Sp1 activation of the cyclin D1
RT   promoter.";
RL   Mol. Cell. Biol. 25:4321-4332(2005).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1826, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1700 (ISOFORMS 2A AND 4),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1702 (ISOFORM 2G),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1697 (ISOFORM 3), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [28]
RP   ACTIVITY REGULATION.
RX   PubMed=22711989; DOI=10.1128/mcb.00416-12;
RA   Kloet S.L., Whiting J.L., Gafken P., Ranish J., Wang E.H.;
RT   "Phosphorylation-dependent regulation of cyclin D1 and cyclin A gene
RT   transcription by TFIID subunits TAF1 and TAF7.";
RL   Mol. Cell. Biol. 32:3358-3369(2012).
RN   [29]
RP   MISCELLANEOUS.
RX   PubMed=23184149; DOI=10.1093/hmg/dds499;
RA   Herzfeld T., Nolte D., Grznarova M., Hofmann A., Schultze J.L., Muller U.;
RT   "X-linked dystonia parkinsonism syndrome (XDP, lubag): disease-specific
RT   sequence change DSC3 in TAF1/DYT3 affects genes in vesicular transport and
RT   dopamine metabolism.";
RL   Hum. Mol. Genet. 22:941-951(2013).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-549 AND LYS-562, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 1359-1638.
RX   PubMed=10827952; DOI=10.1126/science.288.5470.1422;
RA   Jacobson R.H., Ladurner A.G., King D.S., Tjian R.;
RT   "Structure and function of a human TAFII250 double bromodomain module.";
RL   Science 288:1422-1425(2000).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.89 ANGSTROMS) OF 1501-1635, AND SUBUNIT.
RX   PubMed=22464331; DOI=10.1016/j.cell.2012.02.013;
RA   Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P.,
RA   Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T.,
RA   Gingras A.C., Arrowsmith C.H., Knapp S.;
RT   "Histone recognition and large-scale structural analysis of the human
RT   bromodomain family.";
RL   Cell 149:214-231(2012).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 579-1215 IN COMPLEX WITH TAF7,
RP   FUNCTION, AND INTERACTION WITH TAF7.
RX   PubMed=25412659; DOI=10.1038/cr.2014.148;
RA   Wang H., Curran E.C., Hinds T.R., Wang E.H., Zheng N.;
RT   "Crystal structure of a TAF1-TAF7 complex in human transcription factor IID
RT   reveals a promoter binding module.";
RL   Cell Res. 24:1433-1444(2014).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 1497-1638 IN COMPLEX WITH
RP   CROTONYLATED OR BUTYRYLATED HISTONE H4.
RX   PubMed=26365797; DOI=10.1016/j.str.2015.08.004;
RA   Flynn E.M., Huang O.W., Poy F., Oppikofer M., Bellon S.F., Tang Y.,
RA   Cochran A.G.;
RT   "A subset of human bromodomains recognizes butyryllysine and crotonyllysine
RT   histone peptide modifications.";
RL   Structure 23:1801-1814(2015).
RN   [36]
RP   STRUCTURE BY ELECTRON MICROSCOPY (8.50 ANGSTROMS), AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=27007846; DOI=10.1038/nature17394;
RA   Louder R.K., He Y., Lopez-Blanco J.R., Fang J., Chacon P., Nogales E.;
RT   "Structure of promoter-bound TFIID and model of human pre-initiation
RT   complex assembly.";
RL   Nature 531:604-609(2016).
RN   [37] {ECO:0007744|PDB:6FIC}
RP   X-RAY CRYSTALLOGRAPHY (2.18 ANGSTROMS) OF 1359-1638.
RA   Mathea S., Suh J.L., Salah E., Tallant C., Siejka P., Pike A.C.W.,
RA   von Delft F., Arrowsmith C.H., Edwards A.M., Bountra C., James L.I.,
RA   Frye S.V., Knapp S.;
RT   "Bivalent Inhibitor UNC4512 Bound to the TAF1 Bromodomain Tandem.";
RL   Submitted (JAN-2018) to the PDB data bank.
RN   [38] {ECO:0007744|PDB:6P39, ECO:0007744|PDB:6P3A}
RP   X-RAY CRYSTALLOGRAPHY (2.94 ANGSTROMS) OF 1500-1635.
RA   Seo H.-S., Dhe-Paganon S.;
RT   "Crystal Structure Analysis of TAF1 Bromodomain.";
RL   Submitted (MAY-2019) to the PDB data bank.
RN   [39] {ECO:0007744|PDB:7JJG}
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to
RT   ATR kinase inhibitor AZ20.";
RL   Submitted (JUL-2020) to the PDB data bank.
RN   [40] {ECO:0007744|PDB:7JJH}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the unliganded tandem bromodomain (BD1, BD2) of human
RT   TAF1.";
RL   Submitted (JUL-2020) to the PDB data bank.
RN   [41] {ECO:0007744|PDB:7JSP}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to
RT   the ATR kinase inhibitor AZD6738.";
RL   Submitted (AUG-2020) to the PDB data bank.
RN   [42] {ECO:0007744|PDB:7JTC}
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to
RT   ZS1-322.";
RL   Submitted (AUG-2020) to the PDB data bank.
RN   [43] {ECO:0007744|PDB:7K03}
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1 and BD2) of human TAF1
RT   bound to ATR kinase inhibitor AZD6738.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [44] {ECO:0007744|PDB:7K0D}
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound
RT   to mTORC1/2 inhibitor AZD3147.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [45] {ECO:0007744|PDB:7K0U}
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to
RT   PLK1 kinase inhibitor BI2536.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [46] {ECO:0007744|PDB:7K1P}
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to
RT   bromosporine.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [47] {ECO:0007744|PDB:7K27}
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound
RT   to ATR inhibitor AZ20.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [48] {ECO:0007744|PDB:7K3O}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the unliganded second bromodomain (BD2) of human
RT   TAF1.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [49] {ECO:0007744|PDB:7K42}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1501-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the second bromodomain (BD2) of human TAF1 bound to
RT   dioxane.";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [50] {ECO:0007744|PDB:7K6F}
RP   X-RAY CRYSTALLOGRAPHY (1.86 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Bikowitz M.J., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 in
RT   complex with MES (2-(N-morpholino)ethanesulfonic acid).";
RL   Submitted (SEP-2020) to the PDB data bank.
RN   [51] {ECO:0007744|PDB:7L6X}
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound
RT   to GNE-371.";
RL   Submitted (DEC-2020) to the PDB data bank.
RN   [52] {ECO:0007744|PDB:7LB0}
RP   X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound
RT   to ZS1-295.";
RL   Submitted (JAN-2021) to the PDB data bank.
RN   [53] {ECO:0007744|PDB:7LB1}
RP   X-RAY CRYSTALLOGRAPHY (1.35 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound
RT   to ZS1-585.";
RL   Submitted (JAN-2021) to the PDB data bank.
RN   [54] {ECO:0007744|PDB:7LB2}
RP   X-RAY CRYSTALLOGRAPHY (1.70 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain (BD1, BD2) of human TAF1 bound
RT   to ZS1-589.";
RL   Submitted (JAN-2021) to the PDB data bank.
RN   [55] {ECO:0007744|PDB:7N42}
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 1373-1635.
RA   Karim M.R., Schonbrunn E.;
RT   "Crystal structure of the tandem bromodomain of human TAF1 (TAF1-T) bound
RT   to ZS1-681.";
RL   Submitted (JUN-2021) to the PDB data bank.
RN   [56] {ECO:0007744|PDB:7EDX, ECO:0007744|PDB:7EG7, ECO:0007744|PDB:7EG8, ECO:0007744|PDB:7EG9, ECO:0007744|PDB:7EGA, ECO:0007744|PDB:7EGB, ECO:0007744|PDB:7EGC, ECO:0007744|PDB:7EGD, ECO:0007744|PDB:7EGE, ECO:0007744|PDB:7EGH}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.04 ANGSTROMS), FUNCTION, IDENTIFICATION
RP   IN THE TFIID COMPLEX, AND SUBUNIT.
RX   PubMed=33795473; DOI=10.1126/science.aba8490;
RA   Chen X., Qi Y., Wu Z., Wang X., Li J., Zhao D., Hou H., Li Y., Yu Z.,
RA   Liu W., Wang M., Ren Y., Li Z., Yang H., Xu Y.;
RT   "Structural insights into preinitiation complex assembly on core
RT   promoters.";
RL   Science 372:0-0(2021).
RN   [57]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-269; GLY-297; ASP-453; LYS-651 AND
RP   ILE-691.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [58]
RP   INVOLVEMENT IN MRXS33, AND VARIANTS MRXS33 SER-575; ARG-786; HIS-955;
RP   TRP-1225; THR-1316; HIS-1431 AND HIS-1496.
RX   PubMed=26637982; DOI=10.1016/j.ajhg.2015.11.005;
RA   O'Rawe J.A., Wu Y., Doerfel M.J., Rope A.F., Au P.Y., Parboosingh J.S.,
RA   Moon S., Kousi M., Kosma K., Smith C.S., Tzetis M., Schuette J.L.,
RA   Hufnagel R.B., Prada C.E., Martinez F., Orellana C., Crain J.,
RA   Caro-Llopis A., Oltra S., Monfort S., Jimenez-Barron L.T., Swensen J.,
RA   Ellingwood S., Smith R., Fang H., Ospina S., Stegmann S., Den Hollander N.,
RA   Mittelman D., Highnam G., Robison R., Yang E., Faivre L., Roubertie A.,
RA   Riviere J.B., Monaghan K.G., Wang K., Davis E.E., Katsanis N.,
RA   Kalscheuer V.M., Wang E.H., Metcalfe K., Kleefstra T., Innes A.M.,
RA   Kitsiou-Tzeli S., Rosello M., Keegan C.E., Lyon G.J.;
RT   "TAF1 Variants Are Associated with Dysmorphic Features, Intellectual
RT   Disability, and Neurological Manifestations.";
RL   Am. J. Hum. Genet. 97:922-932(2015).
RN   [59]
RP   VARIANTS ASP-472 AND CYS-1169.
RX   PubMed=25644381; DOI=10.1038/mp.2014.193;
RA   Hu H., Haas S.A., Chelly J., Van Esch H., Raynaud M., de Brouwer A.P.,
RA   Weinert S., Froyen G., Frints S.G., Laumonnier F., Zemojtel T., Love M.I.,
RA   Richard H., Emde A.K., Bienek M., Jensen C., Hambrock M., Fischer U.,
RA   Langnick C., Feldkamp M., Wissink-Lindhout W., Lebrun N., Castelnau L.,
RA   Rucci J., Montjean R., Dorseuil O., Billuart P., Stuhlmann T., Shaw M.,
RA   Corbett M.A., Gardner A., Willis-Owen S., Tan C., Friend K.L., Belet S.,
RA   van Roozendaal K.E., Jimenez-Pocquet M., Moizard M.P., Ronce N., Sun R.,
RA   O'Keeffe S., Chenna R., van Boemmel A., Goeke J., Hackett A., Field M.,
RA   Christie L., Boyle J., Haan E., Nelson J., Turner G., Baynam G.,
RA   Gillessen-Kaesbach G., Mueller U., Steinberger D., Budny B.,
RA   Badura-Stronka M., Latos-Bielenska A., Ousager L.B., Wieacker P.,
RA   Rodriguez Criado G., Bondeson M.L., Anneren G., Dufke A., Cohen M.,
RA   Van Maldergem L., Vincent-Delorme C., Echenne B., Simon-Bouy B.,
RA   Kleefstra T., Willemsen M., Fryns J.P., Devriendt K., Ullmann R.,
RA   Vingron M., Wrogemann K., Wienker T.F., Tzschach A., van Bokhoven H.,
RA   Gecz J., Jentsch T.J., Chen W., Ropers H.H., Kalscheuer V.M.;
RT   "X-exome sequencing of 405 unresolved families identifies seven novel
RT   intellectual disability genes.";
RL   Mol. Psychiatry 21:133-148(2016).
CC   -!- FUNCTION: The TFIID basal transcription factor complex plays a major
CC       role in the initiation of RNA polymerase II (Pol II)-dependent
CC       transcription (PubMed:33795473). TFIID recognizes and binds promoters
CC       with or without a TATA box via its subunit TBP, a TATA-box-binding
CC       protein, and promotes assembly of the pre-initiation complex (PIC)
CC       (PubMed:33795473). The TFIID complex consists of TBP and TBP-associated
CC       factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5, TAF6, TAF7,
CC       TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:33795473). TAF1 is
CC       the largest component and core scaffold of the TFIID complex, involved
CC       in nucleating complex assembly (PubMed:25412659, PubMed:27007846,
CC       PubMed:33795473). TAF1 forms a promoter DNA binding subcomplex of
CC       TFIID, together with TAF7 and TAF2 (PubMed:33795473). Contains novel
CC       N- and C-terminal Ser/Thr kinase domains which can autophosphorylate or
CC       transphosphorylate other transcription factors (PubMed:25412659,
CC       PubMed:8625415). Phosphorylates TP53 on 'Thr-55' which leads to MDM2-
CC       mediated degradation of TP53 (PubMed:25412659). Phosphorylates GTF2A1
CC       and GTF2F1 on Ser residues (PubMed:25412659). Possesses DNA-binding
CC       activity (PubMed:25412659). Essential for progression of the G1 phase
CC       of the cell cycle (PubMed:11278496, PubMed:15053879, PubMed:2038334,
CC       PubMed:8450888, PubMed:8625415, PubMed:9660973, PubMed:9858607).
CC       Exhibits histone acetyltransferase activity towards histones H3 and H4
CC       (PubMed:15870300). {ECO:0000269|PubMed:11278496,
CC       ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15870300,
CC       ECO:0000269|PubMed:2038334, ECO:0000269|PubMed:25412659,
CC       ECO:0000269|PubMed:27007846, ECO:0000269|PubMed:33795473,
CC       ECO:0000269|PubMed:8450888, ECO:0000269|PubMed:8625415,
CC       ECO:0000269|PubMed:9660973, ECO:0000269|PubMed:9858607}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=acetyl-CoA + L-lysyl-[protein] = CoA + H(+) + N(6)-acetyl-L-
CC         lysyl-[protein]; Xref=Rhea:RHEA:45948, Rhea:RHEA-COMP:9752,
CC         Rhea:RHEA-COMP:10731, ChEBI:CHEBI:15378, ChEBI:CHEBI:29969,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57288, ChEBI:CHEBI:61930; EC=2.3.1.48;
CC         Evidence={ECO:0000269|PubMed:15870300};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- ACTIVITY REGULATION: Autophosphorylates on Ser residues
CC       (PubMed:8625415). Inhibited by retinoblastoma tumor suppressor protein,
CC       RB1 (PubMed:9858607). Binding to TAF7 or CIITA inhibits the histone
CC       acetyltransferase activity (PubMed:11592977, PubMed:22711989).
CC       {ECO:0000269|PubMed:11592977, ECO:0000269|PubMed:22711989,
CC       ECO:0000269|PubMed:8625415, ECO:0000269|PubMed:9858607}.
CC   -!- SUBUNIT: Component of the TFIID basal transcription factor complex,
CC       composed of TATA-box-binding protein TBP, and a number of TBP-
CC       associated factors (TAFs), including TAF1, TAF2, TAF3, TAF4, TAF5,
CC       TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13 (PubMed:7680771,
CC       PubMed:33795473). Interacts with TAF7; the interaction is direct
CC       (PubMed:25412659, PubMed:11592977). TAF1, when part of the TFIID
CC       complex, interacts with C-terminus of TP53 (PubMed:15053879). Part of a
CC       TFIID-containing RNA polymerase II pre-initiation complex that is
CC       composed of TBP and at least GTF2A1, GTF2A2, GTF2E1, GTF2E2, GTF2F1,
CC       GTF2H2, GTF2H3, GTF2H4, GTF2H5, GTF2B, TCEA1, ERCC2, ERCC3, TAF1, TAF2,
CC       TAF3, TAF4, TAF5, TAF6, TAF7, TAF8, TAF9, TAF10, TAF11, TAF12 and TAF13
CC       (PubMed:27007846). Component of some MLL1/MLL complex, at least
CC       composed of the core components KMT2A/MLL1, ASH2L, HCFC1/HCF1, WDR5 and
CC       RBBP5, as well as the facultative components BAP18, CHD8, E2F6, HSP70,
CC       INO80C, KANSL1, LAS1L, MAX, MCRS1, MGA, KAT8/MOF, PELP1, PHF20, PRP31,
CC       RING2, RUVB1/TIP49A, RUVB2/TIP49B, SENP3, TAF1, TAF4, TAF6, TAF7, TAF9
CC       and TEX10 (PubMed:15960975). RB1 interacts with the N-terminal domain
CC       of TAF1 (PubMed:9858607). Interacts with ASF1A and ASF1B
CC       (PubMed:10759893, PubMed:12093919, PubMed:12842904). Interacts (via
CC       bromo domains) with acetylated lysine residues on the N-terminus of
CC       histone H1.4, H2A, H2B, H3 and H4 (in vitro) (PubMed:22464331).
CC       {ECO:0000269|PubMed:10759893, ECO:0000269|PubMed:11592977,
CC       ECO:0000269|PubMed:12093919, ECO:0000269|PubMed:12842904,
CC       ECO:0000269|PubMed:15053879, ECO:0000269|PubMed:15960975,
CC       ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:25412659,
CC       ECO:0000269|PubMed:27007846, ECO:0000269|PubMed:33795473,
CC       ECO:0000269|PubMed:7680771, ECO:0000269|PubMed:9858607}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with SV40 Large T antigen.
CC       {ECO:0000269|PubMed:8647434}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with herpes simplex virus 1
CC       ICP4. {ECO:0000269|PubMed:8649420}.
CC   -!- INTERACTION:
CC       P21675; P35269: GTF2F1; NbExp=3; IntAct=EBI-491289, EBI-457886;
CC       P21675; P20226: TBP; NbExp=10; IntAct=EBI-491289, EBI-355371;
CC       P21675; P03255; Xeno; NbExp=3; IntAct=EBI-491289, EBI-2603114;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:2038334,
CC       ECO:0000269|PubMed:27007846}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=12;
CC         Comment=the TAF1/DYT3 multiple transcript system is composed of 38
CC         evolutionary conserved exons plus 5 downstream exons referred to as
CC         exons d1-d5 that are primate-specific. Multiple highly polymorphic
CC         variants can be generated by splicing exons d3 and d4 to various
CC         combinations of exons 1-37.;
CC       Name=1;
CC         IsoId=P21675-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P21675-2; Sequence=VSP_012362;
CC       Name=3;
CC         IsoId=P21675-3; Sequence=VSP_053382, VSP_053383, VSP_053384;
CC       Name=4;
CC         IsoId=P21675-4; Sequence=VSP_053383;
CC       Name=2a;
CC         IsoId=P21675-5; Sequence=VSP_053383, VSP_053384;
CC       Name=2c;
CC         IsoId=P21675-6; Sequence=VSP_053384;
CC       Name=2d;
CC         IsoId=P21675-7; Sequence=VSP_053381, VSP_053384;
CC       Name=2e; Synonyms=2F;
CC         IsoId=P21675-8; Sequence=VSP_053379, VSP_053380;
CC       Name=2g;
CC         IsoId=P21675-9; Sequence=VSP_053381, VSP_053383, VSP_053384;
CC       Name=2h;
CC         IsoId=P21675-10; Sequence=VSP_053375, VSP_053377;
CC       Name=2i;
CC         IsoId=P21675-11; Sequence=VSP_053376, VSP_053378;
CC       Name=N-TAF1; Synonyms=TA14-391;
CC         IsoId=P21675-12; Sequence=VSP_012362, VSP_053381;
CC   -!- DOMAIN: The Bromo domain mediates interaction with histones that have
CC       acetylated lysine residues at specific positions (PubMed:22464331). The
CC       second domain also recognizes and binds histones that are butyrylated
CC       and crotonylated (PubMed:26365797). {ECO:0000269|PubMed:22464331,
CC       ECO:0000269|PubMed:26365797}.
CC   -!- PTM: Phosphorylated by casein kinase II in vitro.
CC       {ECO:0000269|PubMed:8625415}.
CC   -!- DISEASE: Dystonia 3, torsion, X-linked (DYT3) [MIM:314250]: An X-linked
CC       dystonia-parkinsonism disorder. Dystonia is defined by the presence of
CC       sustained involuntary muscle contractions, often leading to abnormal
CC       postures. DYT3 is characterized by severe progressive torsion dystonia
CC       followed by parkinsonism. It has a well-defined pathology of extensive
CC       neuronal loss and mosaic gliosis in the striatum (caudate nucleus and
CC       putamen) which appears to resemble that in Huntington disease.
CC       {ECO:0000269|PubMed:12928496, ECO:0000269|PubMed:17273961}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Intellectual developmental disorder, X-linked, syndromic 33
CC       (MRXS33) [MIM:300966]: A syndrome characterized by intellectual
CC       deficit, delayed psychomotor development, delayed speech and language,
CC       and characteristic facial features. {ECO:0000269|PubMed:26637982}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: Isoforms including the downstream (d) exons are
CC       preferentially expressed in brain, and may play a role in the
CC       regulation of genes involved in dopamine processing and transport.
CC   -!- MISCELLANEOUS: [Isoform N-TAF1]: Only detected in brain, highest
CC       expression in the caudate nucleus. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the TAF1 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/taf1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D90359; BAA14374.1; -; mRNA.
DR   EMBL; X07024; CAA30073.1; ALT_SEQ; mRNA.
DR   EMBL; AB300418; BAG15901.1; -; mRNA.
DR   EMBL; AY623109; AAT38105.1; -; Genomic_DNA.
DR   EMBL; AL590762; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590763; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB209316; BAD92553.1; -; mRNA.
DR   EMBL; AJ549247; CAD70490.1; -; mRNA.
DR   EMBL; AJ549248; CAD70491.3; -; mRNA.
DR   EMBL; AJ549249; CAD70492.2; -; mRNA.
DR   EMBL; AJ549250; CAD70493.3; -; mRNA.
DR   EMBL; AJ555148; CAD87527.2; -; mRNA.
DR   EMBL; AJ555149; CAD87528.2; -; mRNA.
DR   EMBL; AM711892; CAM98555.1; -; mRNA.
DR   EMBL; AM711893; CAM98556.1; -; mRNA.
DR   EMBL; AM711894; CAM98557.1; -; mRNA.
DR   EMBL; AM711895; CAM98558.1; -; mRNA.
DR   PIR; A40262; A40262.
DR   RefSeq; NP_001273003.1; NM_001286074.1.
DR   RefSeq; NP_004597.2; NM_004606.4.
DR   RefSeq; NP_620278.1; NM_138923.3.
DR   RefSeq; XP_005262354.1; XM_005262297.4. [P21675-4]
DR   PDB; 1EQF; X-ray; 2.10 A; A=1359-1638.
DR   PDB; 3AAD; X-ray; 3.30 A; A=1342-1629.
DR   PDB; 3UV4; X-ray; 1.89 A; A/B=1501-1635.
DR   PDB; 3UV5; X-ray; 2.03 A; A=1373-1635.
DR   PDB; 4RGW; X-ray; 2.30 A; A=579-1215.
DR   PDB; 4YYM; X-ray; 1.50 A; A/B=1497-1638.
DR   PDB; 4YYN; X-ray; 1.85 A; A/B=1497-1638.
DR   PDB; 5FUR; EM; 8.50 A; G=1-1872.
DR   PDB; 5I1Q; X-ray; 1.50 A; A=1497-1638.
DR   PDB; 5I29; X-ray; 1.21 A; A=1497-1638.
DR   PDB; 5MG2; X-ray; 1.75 A; A=1501-1635.
DR   PDB; 6BQD; X-ray; 2.14 A; A/B=1501-1630.
DR   PDB; 6FIC; X-ray; 2.18 A; T=1359-1638.
DR   PDB; 6MZD; EM; 9.80 A; A=21-1872.
DR   PDB; 6MZL; EM; 23.00 A; A=1-1872.
DR   PDB; 6MZM; EM; 7.50 A; A=588-1083.
DR   PDB; 6P38; X-ray; 2.80 A; A=1501-1635.
DR   PDB; 6P39; X-ray; 2.94 A; A=1500-1635.
DR   PDB; 6P3A; X-ray; 2.99 A; A/B=1501-1635.
DR   PDB; 7EDX; EM; 4.50 A; A=1-1872.
DR   PDB; 7EG7; EM; 6.20 A; A=1-1872.
DR   PDB; 7EG8; EM; 7.40 A; A=1-1872.
DR   PDB; 7EG9; EM; 3.70 A; A=1-1872.
DR   PDB; 7EGA; EM; 4.10 A; A=1-1872.
DR   PDB; 7EGB; EM; 3.30 A; A=1-1872.
DR   PDB; 7EGC; EM; 3.90 A; A=1-1872.
DR   PDB; 7EGD; EM; 6.75 A; A=1-1872.
DR   PDB; 7EGE; EM; 9.00 A; A=1-1872.
DR   PDB; 7EGH; EM; 3.04 A; A=1-1872.
DR   PDB; 7EGI; EM; 9.82 A; A=1-1872.
DR   PDB; 7EGJ; EM; 8.64 A; A=1-1872.
DR   PDB; 7ENA; EM; 4.07 A; DA=1-1872.
DR   PDB; 7ENC; EM; 4.13 A; DA=1-1872.
DR   PDB; 7JJG; X-ray; 1.60 A; A=1501-1635.
DR   PDB; 7JJH; X-ray; 2.10 A; A=1373-1635.
DR   PDB; 7JSP; X-ray; 1.70 A; A=1501-1635.
DR   PDB; 7JTC; X-ray; 2.05 A; A=1501-1635.
DR   PDB; 7K03; X-ray; 1.60 A; A=1373-1635.
DR   PDB; 7K0D; X-ray; 2.20 A; A=1373-1635.
DR   PDB; 7K0U; X-ray; 2.52 A; A/B=1501-1635.
DR   PDB; 7K1P; X-ray; 2.45 A; A=1501-1635.
DR   PDB; 7K27; X-ray; 1.50 A; A=1373-1635.
DR   PDB; 7K3O; X-ray; 1.70 A; A/B=1501-1635.
DR   PDB; 7K42; X-ray; 1.70 A; A/B=1501-1635.
DR   PDB; 7K6F; X-ray; 1.86 A; A=1373-1635.
DR   PDB; 7L6X; X-ray; 2.75 A; A=1373-1635.
DR   PDB; 7LB0; X-ray; 2.33 A; A=1373-1635.
DR   PDB; 7LB1; X-ray; 1.35 A; A=1373-1635.
DR   PDB; 7LB2; X-ray; 1.70 A; A=1373-1635.
DR   PDB; 7LB3; X-ray; 1.90 A; A=1501-1635.
DR   PDB; 7N42; X-ray; 1.90 A; A=1373-1635.
DR   PDB; 7P4S; X-ray; 2.17 A; A=1501-1635.
DR   PDB; 7T2I; X-ray; 1.89 A; A=1373-1635.
DR   PDB; 7T36; X-ray; 1.65 A; A=1373-1635.
DR   PDBsum; 1EQF; -.
DR   PDBsum; 3AAD; -.
DR   PDBsum; 3UV4; -.
DR   PDBsum; 3UV5; -.
DR   PDBsum; 4RGW; -.
DR   PDBsum; 4YYM; -.
DR   PDBsum; 4YYN; -.
DR   PDBsum; 5FUR; -.
DR   PDBsum; 5I1Q; -.
DR   PDBsum; 5I29; -.
DR   PDBsum; 5MG2; -.
DR   PDBsum; 6BQD; -.
DR   PDBsum; 6FIC; -.
DR   PDBsum; 6MZD; -.
DR   PDBsum; 6MZL; -.
DR   PDBsum; 6MZM; -.
DR   PDBsum; 6P38; -.
DR   PDBsum; 6P39; -.
DR   PDBsum; 6P3A; -.
DR   PDBsum; 7EDX; -.
DR   PDBsum; 7EG7; -.
DR   PDBsum; 7EG8; -.
DR   PDBsum; 7EG9; -.
DR   PDBsum; 7EGA; -.
DR   PDBsum; 7EGB; -.
DR   PDBsum; 7EGC; -.
DR   PDBsum; 7EGD; -.
DR   PDBsum; 7EGE; -.
DR   PDBsum; 7EGH; -.
DR   PDBsum; 7EGI; -.
DR   PDBsum; 7EGJ; -.
DR   PDBsum; 7ENA; -.
DR   PDBsum; 7ENC; -.
DR   PDBsum; 7JJG; -.
DR   PDBsum; 7JJH; -.
DR   PDBsum; 7JSP; -.
DR   PDBsum; 7JTC; -.
DR   PDBsum; 7K03; -.
DR   PDBsum; 7K0D; -.
DR   PDBsum; 7K0U; -.
DR   PDBsum; 7K1P; -.
DR   PDBsum; 7K27; -.
DR   PDBsum; 7K3O; -.
DR   PDBsum; 7K42; -.
DR   PDBsum; 7K6F; -.
DR   PDBsum; 7L6X; -.
DR   PDBsum; 7LB0; -.
DR   PDBsum; 7LB1; -.
DR   PDBsum; 7LB2; -.
DR   PDBsum; 7LB3; -.
DR   PDBsum; 7N42; -.
DR   PDBsum; 7P4S; -.
DR   PDBsum; 7T2I; -.
DR   PDBsum; 7T36; -.
DR   AlphaFoldDB; P21675; -.
DR   SASBDB; P21675; -.
DR   SMR; P21675; -.
DR   BioGRID; 112735; 228.
DR   ComplexPortal; CPX-915; General transcription factor complex TFIID.
DR   ComplexPortal; CPX-930; General transcription factor complex TFIID, TAF4B variant.
DR   CORUM; P21675; -.
DR   DIP; DIP-147N; -.
DR   IntAct; P21675; 55.
DR   MINT; P21675; -.
DR   STRING; 9606.ENSP00000406549; -.
DR   BindingDB; P21675; -.
DR   ChEMBL; CHEMBL3217390; -.
DR   GuidetoPHARMACOLOGY; 2231; -.
DR   GlyGen; P21675; 1 site, 1 Thr glycan (1 site).
DR   iPTMnet; P21675; -.
DR   PhosphoSitePlus; P21675; -.
DR   BioMuta; TAF1; -.
DR   DMDM; 115942; -.
DR   EPD; P21675; -.
DR   jPOST; P21675; -.
DR   MassIVE; P21675; -.
DR   MaxQB; P21675; -.
DR   PaxDb; P21675; -.
DR   PeptideAtlas; P21675; -.
DR   PRIDE; P21675; -.
DR   ProteomicsDB; 3401; -.
DR   ProteomicsDB; 53886; -. [P21675-1]
DR   ProteomicsDB; 53887; -. [P21675-2]
DR   ProteomicsDB; 53888; -. [P21675-3]
DR   ProteomicsDB; 53889; -. [P21675-4]
DR   ABCD; P21675; 1 sequenced antibody.
DR   Antibodypedia; 346; 300 antibodies from 36 providers.
DR   DNASU; 6872; -.
DR   Ensembl; ENST00000276072.9; ENSP00000276072.5; ENSG00000147133.17.
DR   Ensembl; ENST00000373790.9; ENSP00000362895.5; ENSG00000147133.17.
DR   Ensembl; ENST00000423759.6; ENSP00000406549.2; ENSG00000147133.17.
DR   GeneID; 6872; -.
DR   KEGG; hsa:6872; -.
DR   UCSC; uc004dzt.6; human. [P21675-1]
DR   CTD; 6872; -.
DR   DisGeNET; 6872; -.
DR   GeneCards; TAF1; -.
DR   GeneReviews; TAF1; -.
DR   HGNC; HGNC:11535; TAF1.
DR   HPA; ENSG00000147133; Low tissue specificity.
DR   MalaCards; TAF1; -.
DR   MIM; 300966; phenotype.
DR   MIM; 313650; gene.
DR   MIM; 314250; phenotype.
DR   neXtProt; NX_P21675; -.
DR   Orphanet; 53351; X-linked dystonia-parkinsonism.
DR   Orphanet; 480907; X-linked intellectual disability-global development delay-facial dysmorphism-sacral caudal remnant syndrome.
DR   PharmGKB; PA36310; -.
DR   VEuPathDB; HostDB:ENSG00000147133; -.
DR   eggNOG; KOG0008; Eukaryota.
DR   HOGENOM; CLU_000572_3_0_1; -.
DR   InParanoid; P21675; -.
DR   OrthoDB; 103411at2759; -.
DR   PhylomeDB; P21675; -.
DR   TreeFam; TF313573; -.
DR   BRENDA; 2.3.1.48; 2681.
DR   PathwayCommons; P21675; -.
DR   Reactome; R-HSA-167161; HIV Transcription Initiation.
DR   Reactome; R-HSA-167162; RNA Polymerase II HIV Promoter Escape.
DR   Reactome; R-HSA-167172; Transcription of the HIV genome.
DR   Reactome; R-HSA-674695; RNA Polymerase II Pre-transcription Events.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-73776; RNA Polymerase II Promoter Escape.
DR   Reactome; R-HSA-73779; RNA Polymerase II Transcription Pre-Initiation And Promoter Opening.
DR   Reactome; R-HSA-75953; RNA Polymerase II Transcription Initiation.
DR   Reactome; R-HSA-76042; RNA Polymerase II Transcription Initiation And Promoter Clearance.
DR   SignaLink; P21675; -.
DR   SIGNOR; P21675; -.
DR   BioGRID-ORCS; 6872; 329 hits in 737 CRISPR screens.
DR   ChiTaRS; TAF1; human.
DR   EvolutionaryTrace; P21675; -.
DR   GeneWiki; TAF1; -.
DR   GenomeRNAi; 6872; -.
DR   Pharos; P21675; Tchem.
DR   PRO; PR:P21675; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P21675; protein.
DR   Bgee; ENSG00000147133; Expressed in sural nerve and 180 other tissues.
DR   ExpressionAtlas; P21675; baseline and differential.
DR   Genevisible; P21675; HS.
DR   GO; GO:0000785; C:chromatin; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0071339; C:MLL1 complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0005669; C:transcription factor TFIID complex; IDA:UniProtKB.
DR   GO; GO:0005667; C:transcription regulator complex; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004402; F:histone acetyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0070577; F:lysine-acetylated histone binding; IDA:BHF-UCL.
DR   GO; GO:0016922; F:nuclear receptor binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0002039; F:p53 binding; IPI:BHF-UCL.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0004672; F:protein kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0001181; F:RNA polymerase I general transcription initiation factor activity; IDA:ARUK-UCL.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0016251; F:RNA polymerase II general transcription initiation factor activity; IDA:BHF-UCL.
DR   GO; GO:0001091; F:RNA polymerase II general transcription initiation factor binding; IPI:BHF-UCL.
DR   GO; GO:0061629; F:RNA polymerase II-specific DNA-binding transcription factor binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0043565; F:sequence-specific DNA binding; ISS:BHF-UCL.
DR   GO; GO:0017025; F:TBP-class protein binding; IPI:BHF-UCL.
DR   GO; GO:0140416; F:transcription regulator inhibitor activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0061631; F:ubiquitin conjugating enzyme activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0071318; P:cellular response to ATP; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0034644; P:cellular response to UV; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030901; P:midbrain development; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0042789; P:mRNA transcription by RNA polymerase II; IDA:ComplexPortal.
DR   GO; GO:0043433; P:negative regulation of DNA-binding transcription factor activity; IDA:ARUK-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1905524; P:negative regulation of protein autoubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1903026; P:negative regulation of RNA polymerase II regulatory region sequence-specific DNA binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:ParkinsonsUK-UCL.
DR   GO; GO:2000059; P:negative regulation of ubiquitin-dependent protein catabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:2000825; P:positive regulation of androgen receptor activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0032092; P:positive regulation of protein binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0060261; P:positive regulation of transcription initiation by RNA polymerase II; IDA:ComplexPortal.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0050821; P:protein stabilization; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1902806; P:regulation of cell cycle G1/S phase transition; TAS:ParkinsonsUK-UCL.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0051123; P:RNA polymerase II preinitiation complex assembly; IPI:ComplexPortal.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; IGI:BHF-UCL.
DR   GO; GO:0036369; P:transcription factor catabolic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006361; P:transcription initiation at RNA polymerase I promoter; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0006367; P:transcription initiation at RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:ParkinsonsUK-UCL.
DR   Gene3D; 1.10.1100.10; -; 1.
DR   Gene3D; 1.20.920.10; -; 2.
DR   IDEAL; IID00545; -.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR040240; TAF1.
DR   InterPro; IPR011177; TAF1_animal.
DR   InterPro; IPR022591; TAF1_HAT_dom.
DR   InterPro; IPR009067; TAF_II_230-bd.
DR   InterPro; IPR036741; TAFII-230_TBP-bd_sf.
DR   InterPro; IPR041670; Znf-CCHC_6.
DR   PANTHER; PTHR13900; PTHR13900; 1.
DR   Pfam; PF00439; Bromodomain; 2.
DR   Pfam; PF12157; DUF3591; 1.
DR   Pfam; PF09247; TBP-binding; 1.
DR   Pfam; PF15288; zf-CCHC_6; 1.
DR   PIRSF; PIRSF003047; TAF1_animal; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00297; BROMO; 2.
DR   SUPFAM; SSF47055; SSF47055; 1.
DR   SUPFAM; SSF47370; SSF47370; 2.
DR   PROSITE; PS00633; BROMODOMAIN_1; 2.
DR   PROSITE; PS50014; BROMODOMAIN_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Acyltransferase; Alternative splicing;
KW   ATP-binding; Bromodomain; Cell cycle; Disease variant; DNA-binding;
KW   Dystonia; Host-virus interaction; Intellectual disability; Isopeptide bond;
KW   Kinase; Nucleotide-binding; Nucleus; Parkinsonism; Phosphoprotein;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation.
FT   CHAIN           1..1872
FT                   /note="Transcription initiation factor TFIID subunit 1"
FT                   /id="PRO_0000211215"
FT   DOMAIN          1..414
FT                   /note="Protein kinase 1"
FT   DOMAIN          1397..1467
FT                   /note="Bromo 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   DOMAIN          1425..1872
FT                   /note="Protein kinase 2"
FT   DOMAIN          1520..1590
FT                   /note="Bromo 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   DNA_BIND        1195..1273
FT                   /note="HMG box; involved in promoter binding"
FT                   /evidence="ECO:0007744|PDB:7EDX, ECO:0007744|PDB:7EG7,
FT                   ECO:0007744|PDB:7EG8, ECO:0007744|PDB:7EG9,
FT                   ECO:0007744|PDB:7EGA, ECO:0007744|PDB:7EGB,
FT                   ECO:0007744|PDB:7EGC, ECO:0007744|PDB:7EGD,
FT                   ECO:0007744|PDB:7EGE, ECO:0007744|PDB:7EGH,
FT                   ECO:0007744|PDB:7EGI, ECO:0007744|PDB:7EGJ"
FT   REGION          149..204
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          513..536
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          517..976
FT                   /note="Histone acetyltransferase (HAT)"
FT   REGION          969..988
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1107..1127
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1137..1156
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1233..1257
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1342..1629
FT                   /note="Interaction with ASF1A and ASF1B"
FT                   /evidence="ECO:0000269|PubMed:12842904"
FT   REGION          1630..1655
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1675..1872
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           1351..1358
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        178..197
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1717..1733
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1737..1751
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1803..1822
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1848..1872
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         137
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8625415"
FT   MOD_RES         307
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:8625415,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         544
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80UV9"
FT   MOD_RES         1669
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80UV9"
FT   MOD_RES         1672
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80UV9"
FT   MOD_RES         1778
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80UV9"
FT   MOD_RES         1781
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80UV9"
FT   MOD_RES         1799
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80UV9"
FT   MOD_RES         1826
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332"
FT   CROSSLNK        549
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        562
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   VAR_SEQ         177
FT                   /note="G -> GVSENGEGIILPSIIAPSSLAS (in isoform 2 and
FT                   isoform N-TAF1)"
FT                   /evidence="ECO:0000303|PubMed:17273961"
FT                   /id="VSP_012362"
FT   VAR_SEQ         1525..1540
FT                   /note="SWPFHHPVNKKFVPDY -> VSCLCAKYFLAISSPS (in isoform
FT                   2i)"
FT                   /evidence="ECO:0000303|PubMed:17952504"
FT                   /id="VSP_053376"
FT   VAR_SEQ         1525..1528
FT                   /note="SWPF -> IITK (in isoform 2h)"
FT                   /evidence="ECO:0000303|PubMed:17952504"
FT                   /id="VSP_053375"
FT   VAR_SEQ         1529..1872
FT                   /note="Missing (in isoform 2h)"
FT                   /evidence="ECO:0000303|PubMed:17952504"
FT                   /id="VSP_053377"
FT   VAR_SEQ         1541..1872
FT                   /note="Missing (in isoform 2i)"
FT                   /evidence="ECO:0000303|PubMed:17952504"
FT                   /id="VSP_053378"
FT   VAR_SEQ         1585..1592
FT                   /note="PESQYTKT -> YMCTTCRT (in isoform 2e)"
FT                   /evidence="ECO:0000303|PubMed:12928496,
FT                   ECO:0000303|PubMed:17952504"
FT                   /id="VSP_053379"
FT   VAR_SEQ         1593..1872
FT                   /note="Missing (in isoform 2e)"
FT                   /evidence="ECO:0000303|PubMed:12928496,
FT                   ECO:0000303|PubMed:17952504"
FT                   /id="VSP_053380"
FT   VAR_SEQ         1645
FT                   /note="Q -> QAK (in isoform 2d, isoform 2g and isoform
FT                   N-TAF1)"
FT                   /evidence="ECO:0000303|PubMed:12928496,
FT                   ECO:0000303|PubMed:17273961, ECO:0000303|PubMed:17952504"
FT                   /id="VSP_053381"
FT   VAR_SEQ         1684..1686
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:12928496"
FT                   /id="VSP_053382"
FT   VAR_SEQ         1687
FT                   /note="Q -> QMRQGRGRLGEEDSDVDIEGYDDEEEDGKPKTPAP (in isoform
FT                   2g, isoform 2a, isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:12928496,
FT                   ECO:0000303|PubMed:17952504, ECO:0000303|Ref.7"
FT                   /id="VSP_053383"
FT   VAR_SEQ         1799..1872
FT                   /note="SYGSYEEPDPKSNTQDTSFSSIGGYEVSEEEEDEEEEEQRSGPSVLSQVHLS
FT                   EDEEDSEDFHSIAGDSDLDSDE -> RYQ (in isoform 2g, isoform 2a,
FT                   isoform 2c, isoform 2d and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:12928496,
FT                   ECO:0000303|PubMed:17952504"
FT                   /id="VSP_053384"
FT   VARIANT         269
FT                   /note="L -> V (in dbSNP:rs28382158)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.5"
FT                   /id="VAR_020678"
FT   VARIANT         297
FT                   /note="A -> G (in dbSNP:rs35317750)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041930"
FT   VARIANT         453
FT                   /note="G -> D (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041931"
FT   VARIANT         472
FT                   /note="N -> D (found in a patient with X-linked
FT                   intellectual disability; unknown pathological significance;
FT                   dbSNP:rs200177996)"
FT                   /evidence="ECO:0000269|PubMed:25644381"
FT                   /id="VAR_077838"
FT   VARIANT         575
FT                   /note="P -> S (in MRXS33; dbSNP:rs864321630)"
FT                   /evidence="ECO:0000269|PubMed:26637982"
FT                   /id="VAR_076394"
FT   VARIANT         651
FT                   /note="E -> K (in a metastatic melanoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041932"
FT   VARIANT         691
FT                   /note="M -> I (in a lung bronchoalveolar carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041933"
FT   VARIANT         786
FT                   /note="C -> R (in MRXS33; dbSNP:rs864321628)"
FT                   /evidence="ECO:0000269|PubMed:26637982"
FT                   /id="VAR_076395"
FT   VARIANT         955
FT                   /note="D -> H (in MRXS33; dbSNP:rs864321631)"
FT                   /evidence="ECO:0000269|PubMed:26637982"
FT                   /id="VAR_076396"
FT   VARIANT         1169
FT                   /note="R -> C (found in a patient with X-linked
FT                   intellectual disability; unknown pathological significance;
FT                   dbSNP:rs1569301036)"
FT                   /evidence="ECO:0000269|PubMed:25644381"
FT                   /id="VAR_077839"
FT   VARIANT         1225
FT                   /note="R -> W (in MRXS33; dbSNP:rs864321629)"
FT                   /evidence="ECO:0000269|PubMed:26637982"
FT                   /id="VAR_076397"
FT   VARIANT         1316
FT                   /note="I -> T (in MRXS33; dbSNP:rs864321627)"
FT                   /evidence="ECO:0000269|PubMed:26637982"
FT                   /id="VAR_076398"
FT   VARIANT         1383
FT                   /note="V -> I (in dbSNP:rs7050748)"
FT                   /id="VAR_048433"
FT   VARIANT         1431
FT                   /note="R -> H (in MRXS33; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:26637982"
FT                   /id="VAR_076399"
FT   VARIANT         1496
FT                   /note="N -> H (in MRXS33; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:26637982"
FT                   /id="VAR_076400"
FT   MUTAGEN         137
FT                   /note="S->A: No decrease in kinase activity."
FT                   /evidence="ECO:0000269|PubMed:9660973"
FT   MUTAGEN         145
FT                   /note="D->A: Reduces kinase activity; when associated with
FT                   A-147; A-149; A-150; A-152 and A-154."
FT                   /evidence="ECO:0000269|PubMed:9660973"
FT   MUTAGEN         147
FT                   /note="D->A: Reduces kinase activity; when associated with
FT                   A-145; A-149; A-150; A-152 and A-154."
FT                   /evidence="ECO:0000269|PubMed:9660973"
FT   MUTAGEN         149
FT                   /note="E->A: Reduces kinase activity; when associated with
FT                   A-145; A-147; A-150; A-152 and A-154."
FT                   /evidence="ECO:0000269|PubMed:9660973"
FT   MUTAGEN         150
FT                   /note="D->A: Reduces kinase activity; when associated with
FT                   A-145; A-147; A-149; A-152 and A-154."
FT                   /evidence="ECO:0000269|PubMed:9660973"
FT   MUTAGEN         152
FT                   /note="D->A: Reduces kinase activity; when associated with
FT                   A-145; A-147; A-149; A-150 and A-154."
FT                   /evidence="ECO:0000269|PubMed:9660973"
FT   MUTAGEN         154
FT                   /note="K->A: Reduces kinase activity; when associated with
FT                   A-145; A-147; A-149; A-150 and A-152."
FT                   /evidence="ECO:0000269|PubMed:9660973"
FT   MUTAGEN         305
FT                   /note="C->A: Reduces kinase activity; when associated with
FT                   A-307; A-308; A-309 and A-310."
FT                   /evidence="ECO:0000269|PubMed:9660973"
FT   MUTAGEN         307
FT                   /note="S->A: Reduces kinase activity; when associated with
FT                   A-305; A-308; A-309 and A-310."
FT                   /evidence="ECO:0000269|PubMed:9660973"
FT   MUTAGEN         308
FT                   /note="D->A: Reduces kinase activity; when associated with
FT                   A-305; A-307; A-309 and A-310."
FT                   /evidence="ECO:0000269|PubMed:9660973"
FT   MUTAGEN         309
FT                   /note="D->A: Reduces kinase activity; when associated with
FT                   A-305; A-307; A-308 and A-310."
FT                   /evidence="ECO:0000269|PubMed:9660973"
FT   MUTAGEN         310
FT                   /note="E->A: Reduces kinase activity; when associated with
FT                   A-305; A-307; A-308 and A-309."
FT                   /evidence="ECO:0000269|PubMed:9660973"
FT   MUTAGEN         721
FT                   /note="E->Q: 25% decrease in histone acetylation."
FT                   /evidence="ECO:0000269|PubMed:15870300"
FT   MUTAGEN         827..829
FT                   /note="Missing: Dramatic decrease in histone acetylation."
FT                   /evidence="ECO:0000269|PubMed:15870300"
FT   STRAND          342..344
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           347..353
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           399..402
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   STRAND          406..408
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           410..413
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           473..477
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           480..483
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   STRAND          488..490
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   STRAND          504..506
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           570..573
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           593..596
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   TURN            600..602
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           609..613
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   TURN            614..616
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          624..626
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           627..629
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          630..632
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          634..638
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           640..655
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   TURN            656..658
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           668..671
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          675..685
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          697..704
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          708..710
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          718..724
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          729..732
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          739..756
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          761..767
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          770..774
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          778..782
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           797..817
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          820..822
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          824..826
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           827..833
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           839..847
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          850..853
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          856..858
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          861..864
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           873..879
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           882..900
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           905..907
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           925..928
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           931..942
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          947..952
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          958..962
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          964..968
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   HELIX           993..997
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           999..1010
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           1014..1018
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           1022..1034
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           1055..1078
FT                   /evidence="ECO:0007829|PDB:4RGW"
FT   STRAND          1165..1170
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   TURN            1174..1176
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   STRAND          1180..1185
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           1188..1203
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           1217..1241
FT                   /evidence="ECO:0007829|PDB:7EGH"
FT   HELIX           1381..1397
FT                   /evidence="ECO:0007829|PDB:7LB1"
FT   HELIX           1403..1405
FT                   /evidence="ECO:0007829|PDB:7LB1"
FT   STRAND          1406..1408
FT                   /evidence="ECO:0007829|PDB:3AAD"
FT   TURN            1411..1413
FT                   /evidence="ECO:0007829|PDB:7LB1"
FT   HELIX           1417..1420
FT                   /evidence="ECO:0007829|PDB:7LB1"
FT   HELIX           1427..1435
FT                   /evidence="ECO:0007829|PDB:7LB1"
FT   HELIX           1442..1459
FT                   /evidence="ECO:0007829|PDB:7LB1"
FT   STRAND          1462..1464
FT                   /evidence="ECO:0007829|PDB:3AAD"
FT   HELIX           1465..1483
FT                   /evidence="ECO:0007829|PDB:7LB1"
FT   HELIX           1485..1495
FT                   /evidence="ECO:0007829|PDB:7LB1"
FT   HELIX           1497..1500
FT                   /evidence="ECO:0007829|PDB:7LB1"
FT   HELIX           1502..1517
FT                   /evidence="ECO:0007829|PDB:5I29"
FT   TURN            1518..1521
FT                   /evidence="ECO:0007829|PDB:5I29"
FT   HELIX           1526..1528
FT                   /evidence="ECO:0007829|PDB:5I29"
FT   TURN            1534..1536
FT                   /evidence="ECO:0007829|PDB:5I29"
FT   STRAND          1537..1539
FT                   /evidence="ECO:0007829|PDB:6P3A"
FT   HELIX           1540..1543
FT                   /evidence="ECO:0007829|PDB:5I29"
FT   STRAND          1544..1546
FT                   /evidence="ECO:0007829|PDB:6P3A"
FT   HELIX           1550..1558
FT                   /evidence="ECO:0007829|PDB:5I29"
FT   HELIX           1565..1583
FT                   /evidence="ECO:0007829|PDB:5I29"
FT   STRAND          1585..1587
FT                   /evidence="ECO:0007829|PDB:7K6F"
FT   HELIX           1588..1606
FT                   /evidence="ECO:0007829|PDB:5I29"
FT   HELIX           1608..1634
FT                   /evidence="ECO:0007829|PDB:5I29"
FT   MOD_RES         P21675-3:1697
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         P21675-4:1700
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         P21675-5:1700
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         P21675-9:1702
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
SQ   SEQUENCE   1872 AA;  212677 MW;  93BE3D181A72ABEB CRC64;
     MGPGCDLLLR TAATITAAAI MSDTDSDEDS AGGGPFSLAG FLFGNINGAG QLEGESVLDD
     ECKKHLAGLG ALGLGSLITE LTANEELTGT DGALVNDEGW VRSTEDAVDY SDINEVAEDE
     SRRYQQTMGS LQPLCHSDYD EDDYDADCED IDCKLMPPPP PPPGPMKKDK DQDSITGEKV
     DFSSSSDSES EMGPQEATQA ESEDGKLTLP LAGIMQHDAT KLLPSVTELF PEFRPGKVLR
     FLRLFGPGKN VPSVWRSARR KRKKKHRELI QEEQIQEVEC SVESEVSQKS LWNYDYAPPP
     PPEQCLSDDE ITMMAPVESK FSQSTGDIDK VTDTKPRVAE WRYGPARLWY DMLGVPEDGS
     GFDYGFKLRK TEHEPVIKSR MIEEFRKLEE NNGTDLLADE NFLMVTQLHW EDDIIWDGED
     VKHKGTKPQR ASLAGWLPSS MTRNAMAYNV QQGFAATLDD DKPWYSIFPI DNEDLVYGRW
     EDNIIWDAQA MPRLLEPPVL TLDPNDENLI LEIPDEKEEA TSNSPSKESK KESSLKKSRI
     LLGKTGVIKE EPQQNMSQPE VKDPWNLSND EYYYPKQQGL RGTFGGNIIQ HSIPAVELRQ
     PFFPTHMGPI KLRQFHRPPL KKYSFGALSQ PGPHSVQPLL KHIKKKAKMR EQERQASGGG
     EMFFMRTPQD LTGKDGDLIL AEYSEENGPL MMQVGMATKI KNYYKRKPGK DPGAPDCKYG
     ETVYCHTSPF LGSLHPGQLL QAFENNLFRA PIYLHKMPET DFLIIRTRQG YYIRELVDIF
     VVGQQCPLFE VPGPNSKRAN THIRDFLQVF IYRLFWKSKD RPRRIRMEDI KKAFPSHSES
     SIRKRLKLCA DFKRTGMDSN WWVLKSDFRL PTEEEIRAMV SPEQCCAYYS MIAAEQRLKD
     AGYGEKSFFA PEEENEEDFQ MKIDDEVRTA PWNTTRAFIA AMKGKCLLEV TGVADPTGCG
     EGFSYVKIPN KPTQQKDDKE PQPVKKTVTG TDADLRRLSL KNAKQLLRKF GVPEEEIKKL
     SRWEVIDVVR TMSTEQARSG EGPMSKFARG SRFSVAEHQE RYKEECQRIF DLQNKVLSST
     EVLSTDTDSS SAEDSDFEEM GKNIENMLQN KKTSSQLSRE REEQERKELQ RMLLAAGSAA
     SGNNHRDDDT ASVTSLNSSA TGRCLKIYRT FRDEEGKEYV RCETVRKPAV IDAYVRIRTT
     KDEEFIRKFA LFDEQHREEM RKERRRIQEQ LRRLKRNQEK EKLKGPPEKK PKKMKERPDL
     KLKCGACGAI GHMRTNKFCP LYYQTNAPPS NPVAMTEEQE EELEKTVIHN DNEELIKVEG
     TKIVLGKQLI ESADEVRRKS LVLKFPKQQL PPKKKRRVGT TVHCDYLNRP HKSIHRRRTD
     PMVTLSSILE SIINDMRDLP NTYPFHTPVN AKVVKDYYKI ITRPMDLQTL RENVRKRLYP
     SREEFREHLE LIVKNSATYN GPKHSLTQIS QSMLDLCDEK LKEKEDKLAR LEKAINPLLD
     DDDQVAFSFI LDNIVTQKMM AVPDSWPFHH PVNKKFVPDY YKVIVNPMDL ETIRKNISKH
     KYQSRESFLD DVNLILANSV KYNGPESQYT KTAQEIVNVC YQTLTEYDEH LTQLEKDICT
     AKEAALEEAE LESLDPMTPG PYTPQPPDLY DTNTSLSMSR DASVFQDESN MSVLDIPSAT
     PEKQVTQEGE DGDGDLADEE EGTVQQPQAS VLYEDLLMSE GEDDEEDAGS DEEGDNPFSA
     IQLSESGSDS DVGSGGIRPK QPRMLQENTR MDMENEESMM SYEGDGGEAS HGLEDSNISY
     GSYEEPDPKS NTQDTSFSSI GGYEVSEEEE DEEEEEQRSG PSVLSQVHLS EDEEDSEDFH
     SIAGDSDLDS DE
//
